Stock VSTM VERASTEM, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Verastem, Inc.

Equities

VSTM

US92337C2035

Market Closed - Nasdaq
Other stock markets
 01:30:00 22/06/2024 am IST 		5-day change 1st Jan Change
3.16 USD -2.77% Intraday chart for Verastem, Inc. -8.93% -61.18%
28/05 RBC Halves Price Target on Verastem to $16 From $32, Maintains Outperform Rating, Speculative Risk Qualifier MT
24/05 Top Midday Decliners MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Midday Decliners
MT
Sector Update: Health Care Stocks Advance Pre-Bell Friday
MT
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
MT
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer
CI
Verastem, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Verastem, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Verastem, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Verastem Oncology's Ovarian Cancer Drug Gets FDA Orphan Drug Designation
DJ
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers
CI
Verastem Gets Fast Track Label For Avutometinib Combination in Non-Small Cell Lung Cancer
MT
Verastem Gets FDA Fast-Track Approval on Lung Cancer Treatment
DJ
Verastem Oncology Selects Oral Kras G12d Inhibitor Gfh375/Vs-7375 as Lead Program in Discovery and Development Collaboration with Genfleet Therapeutics
CI
Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
CI
Verastem Oncology Announces the Launch of the New Healthcare Professional Component
CI
Verastem, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS? in KRAS G12C-Mutant Non-Small Cell Lung Cancer
CI
Verastem Partners With GenFleet Therapeutics to Advance Oncology Discovery Programs
MT
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting Ras Pathway-Driven Cancers
CI
Verastem, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VSTM Stock
  4. News Verastem, Inc.
  5. Highlights